Thumbnail Image
Publication

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Sydes, M
; 
Spears, M
; 
Mason, M
; 
Clarke, Noel W
; 
Dearnaley, D
; 
de Bono, J
; 
Attard, G
; 
Chowdhury, S
; 
Cross, B
; 
Gillessen, S
... show 10 more
Citations
Altmetric:
Abstract
Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative data of SOC+AAP vs SOC+DocP.
Authors
Sydes, M
Spears, M
Mason, M
Clarke, Noel W
Dearnaley, D
de Bono, J
Attard, G
Chowdhury, S
Cross, B
Gillessen, S
Malik, Z
Jones, R
Parker, C
Ritchie, A
Russell, J
Millman, R
Matheson, D
Amos, C
Gilson, C
Birtle, A
Brock, S
Capaldi, L
Chakraborti, P
Choudhury, Ananya
Evans, L
Ford, D
Gale, J
Gibbs, S
Gilbert, D
Hughes, R
McLaren, D
Lester, J
Nikapota, A
O'Sullivan, J
Parikh, O
Peedell, C
Protheroe, A
Rudman, S
Shaffer, R
Sheehan, D
Simms, M
Srihari, N
Strebel, R
Sundar, S
Tolan, S
Tsang, D
Varughese, M
Wagstaff, J
Parmar, M
James, N
Affiliation
MRC Clinical Trials Unit at UCL, London, UKMRC Clinical Trials Unit at UCL, London, UK
Description
Date
2018-02-26
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Full text, Open Access article
Adobe PDF, 494.6 KB
Keywords
Type
Article
Citation
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 2018, Ann Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620908
Embedded videos